Welcome to our dedicated page for Gentherm news (Ticker: THRM), a resource for investors and traders seeking the latest updates and insights on Gentherm stock.
Gentherm Inc. reports developments in thermal management and pneumatic comfort technologies for automotive and medical markets. Its Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, Valve Systems, cable systems, battery performance solutions, and automotive electronics and software systems. Its Medical business covers patient temperature management systems and related device technology.
Recurring news includes quarterly and annual results, conference participation, automotive new-business activity, shareholder voting matters, and medical-device regulatory updates. Company announcements also cover ThermAffyx™ Patient Safety System, an integrated patient warming and securement system submitted through the FDA 510(k) pathway, and communications activity around Gentherm Medical products.
Gentherm (NASDAQ:THRM) will participate in several Q2 2026 investor conferences. Key appearances include a fireside chat at the Baird Global Consumer, Technology & Services Conference in New York on June 3, 2026, starting at 8:30 a.m. ET and lasting about 30 minutes.
A live audio webcast and 90-day replay will be available on Gentherm’s Investor Relations Events page. Management will also attend the Stifel Cross Sector 1x1 Conference on June 2, 2026, in Boston and the Wells Fargo Industrials & Materials Conference on June 9, 2026, in Chicago. Dates and participation may change; investors are directed to the Gentherm Investor Relations website for updates.
Gentherm (NASDAQ: THRM) will showcase its science-backed WellSense wellness technologies for home and office furniture at NeoCon 2026 in Chicago, including Preview Day on June 7 and exhibits June 8–10.
Demonstrations include wellness recliners, office chairs, smart desks, and medical seating built on extensive human physiology research.
Gentherm (NASDAQ:THRM) reported record Q1 2026 product revenue of $393.7M (11.3% YoY; 7.2% ex-FX), gross margin of 24.7%, net income of $4.2M, and adjusted EBITDA of $49.3M (12.5% margin). The company announced a planned combination with Modine Performance Technologies and submitted a 510(k) for ThermAffyx, expecting revenue in Q3 2026.
Full-year 2026 guidance remains: Product Revenues $1.5B–$1.6B, Adjusted EBITDA $175M–$195M, Adjusted FCF $80M–$100M. Net leverage ~0.2x and liquidity $455.5M.
Gentherm (NASDAQ: THRM) will report first‑quarter 2026 financial results on Thursday, April 23, 2026 and will host a conference call at 8:00 AM ET the same day.
Dial‑in numbers, webcast access, and replay details are provided; the telephonic replay and webcast archive will be available until May 7, 2026. Investor and media contact information is listed for follow‑up.
Gentherm (NASDAQ: THRM) announced a product launch with KUKA Home in Asia on March 19, 2026, extending Gentherm’s thermal and pneumatic comfort technologies from automotive into home furniture applications.
According to the company, the co-branded program “Enhanced Comfort by Gentherm” moves projects from development into production and underscores scalable, consumer-focused integration and speed-to-market.
Gentherm (NASDAQ: THRM) will participate in the 38th Annual ROTH Conference in Dana Point, California. Bill Presley, President and CEO, and Jon Douyard, Executive Vice President, Chief Financial Officer and Treasurer, will host investor meetings on March 23–24, 2026.
Event dates and participation are subject to change; investors should check the Gentherm Investor Relations website for the latest scheduling and registration details.
Gentherm (NASDAQ:THRM) named KNB Communications as agency of record to support the launch of the ThermAffyx™ Patient Safety System, a first-of-its-kind device integrating patient warming and securement for surgery. Gentherm submitted a 510(k) Class II premarket notification and expects FDA clearance in May 2026.
KNB will lead strategic healthcare communications to raise awareness among clinicians, investors, and patients ahead of anticipated regulatory clearance and commercial rollout.
Gentherm (NASDAQ:THRM) reported record 2025 product revenues of $1.4986 billion and full-year cash flow from operations of $116.8 million. The company secured $2.2 billion of automotive new business awards in 2025 and reduced net leverage to ~0.2x.
Q4 product revenue was $382.8 million, GAAP net income was $3.0 million, and adjusted EBITDA for 2025 was $174.8 million (11.7% of revenue). 2026 guidance: product revenues $1.5–$1.6B, adjusted EBITDA $175–$195M, adjusted free cash flow $80–$100M; 2027 preliminary product revenue outlook ~$1.7 billion.
Gentherm (NASDAQ: THRM) will report fourth-quarter and year-end 2025 financial results on Thursday, February 19, 2026, and will host a conference call at 8:00 AM ET the same day. A live webcast and one-year archived replay will be available on the company's Investor Relations Events page.
Toll-free dial-in, international numbers, conference ID, and telephonic replay details are provided for investor access; replay is available until 11:59 PM ET on March 5, 2026. Investor and media contact information is listed for follow-up.
Gentherm (NASDAQ: THRM) submitted a 510(k) Class II premarket notification to the U.S. Food and Drug Administration on Feb. 3, 2026 for ThermAffyx™ Patient Safety System, an integrated patient warming and securement device. The company plans a market launch in the third quarter of 2026.
The ThermAffyx system combines air-free warming with securement to address intraoperative hypothermia and patient movement in procedures using Trendelenburg positioning. FDA clearance is expected in the first half of 2026, and the product adapts thermal technology from Gentherm’s automotive business for medical use.